Treatment with dupilumab is safe and effective for patients with bullous pemphigoid, with complete remission seen as early as 4 weeks of treatment.

Several adverse health outcomes are associated with AD, such as atopic and allergic conditions, immune mediated conditions, and more.

The FDA has approved Bimzelx® (bimekizumab-bkzx) for the treatment of moderate to severe hidradenitis suppurativa in adults.

From 2021 to 2022, there was a decrease in the number of abortions performed, as well as in the abortion rate and ratio.

Adhering to a healthy prenatal diet may reduce patterns of infant growth outside reference ranges, according to study findings.

Work-time, rather than leisure-time or nonworkday, activity behavior seems to be associated with 24-hour ambulatory blood pressure.

COVID-19, influenza, and RSV vaccination coverage is low among nursing home residents early in the 2024 to 2025 season.

Poor control over specific aspects of work is associated with burnout among physicians, according to study findings.

Vaccination of 27- to 45-year-olds against HPV is less cost-effective than vaccination of younger persons (aged 9 to 26 years).

Baricitinib is an effective treatment option for children and adolescents with atopic dermatitis, with no new safety signals identified.

Deucravacitinib outperformed placebo for treating moderate to severe scalp psoriasis, even among patients with less extensive overall disease.

Tumor characteristics differ significantly among pediatric and adolescent and young AYA patients with melanoma, with decreasing incidence rates seen among young patients with cutaneous melanoma.